Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

PubWeight™: 1.79‹?› | Rank: Top 3%

🔗 View Article (PMID 9663484)

Published in Arthritis Rheum on July 01, 1998

Authors

E M Paleolog1, S Young, A C Stark, R V McCloskey, M Feldmann, R N Maini

Author Affiliations

1: Kennedy Institute of Rheumatology, London, UK.

Articles citing this

TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol (2007) 2.17

Oxidation in rheumatoid arthritis. Arthritis Res Ther (2004) 1.96

Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J (2000) 1.66

Angiogenesis in rheumatoid arthritis. Arthritis Res (2002) 1.58

Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res (2000) 1.50

Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis (2003) 1.49

Hypoxia--a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol (2012) 1.41

Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis (2002) 1.38

Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis (2001) 1.35

Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med (2009) 1.29

Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther (2007) 1.23

Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther (2003) 1.20

How does infliximab work in rheumatoid arthritis? Arthritis Res (2002) 1.20

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis (1999) 1.12

Hypoxia. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis. Arthritis Res Ther (2009) 1.09

Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis (2002) 1.09

Effects of ginseng saponins isolated from Red Ginseng roots on burn wound healing in mice. Br J Pharmacol (2006) 1.07

Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Arthritis Res Ther (2008) 1.05

IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol (2005) 1.03

VEGF and imaging of vessels in rheumatoid arthritis. Arthritis Res (2002) 1.03

Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol Int (2007) 1.02

The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis (2000) 1.02

IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int (2009) 0.97

The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol (2009) 0.97

Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus. Arthritis Res Ther (2004) 0.97

Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther (2009) 0.97

Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One (2009) 0.96

Methionine aminopeptidase-2 blockade reduces chronic collagen-induced arthritis: potential role for angiogenesis inhibition. Arthritis Res Ther (2007) 0.95

Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 0.94

Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Clin Exp Immunol (2007) 0.93

Anti-angiogenic effect of triptolide in rheumatoid arthritis by targeting angiogenic cascade. PLoS One (2013) 0.91

New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol (1999) 0.91

The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther (2002) 0.90

TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br J Cancer (2004) 0.89

Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis (1999) 0.89

The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1α in human rheumatoid arthritis fibroblast-like synoviocyte. Rheumatol Int (2009) 0.88

Molecular targeting of hepatocyte growth factor by an antagonist, NK4, in the treatment of rheumatoid arthritis. Arthritis Res Ther (2013) 0.87

The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis. Clin Rheumatol (2010) 0.87

Tumour necrosis factor-alpha (TNF-alpha) enhances lymphocyte migration into rheumatoid synovial tissue transplanted into severe combined immunodeficient (SCID) mice. Clin Exp Immunol (2000) 0.87

c-Jun N-Terminal Kinase in Inflammation and Rheumatic Diseases. Open Rheumatol J (2012) 0.85

Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane. Rheumatol Int (2006) 0.85

A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin Rheumatol (2005) 0.85

Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J (2005) 0.84

Inhibition of HMGB1-induced angiogenesis by cilostazol via SIRT1 activation in synovial fibroblasts from rheumatoid arthritis. PLoS One (2014) 0.83

Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol Int (2005) 0.82

Gene expression profiling and functional analysis of angiogenic markers in murine collagen-induced arthritis. Arthritis Res Ther (2012) 0.82

Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol (2006) 0.81

The role of IL-33 in rheumatic diseases. Clin Dev Immunol (2013) 0.80

A new strategy to deliver synthetic protein drugs: self-reproducible biologics using minicircles. Sci Rep (2014) 0.80

Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int (2007) 0.79

A role for type 1alpha corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue. Am J Pathol (2007) 0.79

A follow-up to "Anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg. Arthritis Res (2001) 0.79

Future prospects for anti-cytokine treatment. Ann Rheum Dis (2000) 0.79

Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate. Rheumatol Int (2003) 0.78

Hypoxia: not merely a regulator of angiogenesis? Arthritis Res Ther (2004) 0.78

Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Biomark Insights (2009) 0.76

Chemical Hypoxia Brings to Light Altered Autocrine Sphingosine-1-Phosphate Signalling in Rheumatoid Arthritis Synovial Fibroblasts. Mediators Inflamm (2015) 0.76

Expression of the VEGF receptor-3 in osteoarthritic chondrocytes: stimulation by interleukin-1 beta and association with beta 1-integrins. Histochem Cell Biol (2003) 0.76

Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. Arthritis Res Ther (2016) 0.75

Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α. PLoS One (2016) 0.75

[Angiogenesis. Possibilities for therapeutic intervention in rheumatic diseases]. Z Rheumatol (2007) 0.75

Articles by these authors

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet (1999) 11.92

Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 10.22

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46

Rheumatoid arthritis. Cell (1996) 6.01

Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet (1983) 5.64

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol (2001) 5.59

The role of macrophages in the generation of T-helper cells. II. The genetic control of the macrophage-T-cell interaction for helper cell induction with soluble antigens. J Exp Med (1975) 5.48

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05

Delays in the diagnosis of oesophagogastric cancer: a consecutive case series. BMJ (1997) 5.02

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 4.42

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum (2005) 4.28

Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20

The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J Exp Med (1971) 4.03

The complete primary structure of protein kinase C--the major phorbol ester receptor. Science (1986) 4.02

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation (1996) 4.01

Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother (1983) 3.83

Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin. J Exp Med (1972) 3.57

Chronic wasting disease of captive mule deer: a spongiform encephalopathy. J Wildl Dis (1980) 3.53

Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med (1983) 3.52

A micro-method for peripheral leucocyte migration in tuberculin sensitivity. J Clin Pathol (1971) 3.45

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35

Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29

Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol (1985) 3.18

Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature (1985) 3.11

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06

A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem (1982) 3.04

Separation of suppressor and killer T cells by surgace phenotype. Nature (1976) 3.03

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A (2000) 3.00

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96

HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature (1987) 2.96

Different Ly antigen phenotypes of in vitro induced helper and suppressor cells. Nature (1975) 2.91

Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 2.90

Dendritic cells induce T cell proliferation to synthetic antigens under Ir gene control. J Exp Med (1980) 2.88

Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol (1996) 2.85

Possible new method to improve detection of diabetic retinopathy: Polaroid non-mydriatic retinal photography. Br Med J (Clin Res Ed) (1985) 2.83

Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology (2005) 2.79

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74

Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry (2006) 2.65

T-cell lines producing antigen-specific suppressor factor. Nature (1978) 2.63

Induction of immunity and tolerance in vitro by hapten protein conjugates. I. The relationship between the degree of hapten conjugation and the immunogenicity of dinitrophenylated polymerized flagellin. J Exp Med (1972) 2.52

Cell interactions in the immune response in vitro. IV. Comparison of the effects of antigen-specific and allogeneic thymus-derived cell factors. J Exp Med (1972) 2.48

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45

Tolerance, enhancement and the regulation of interactions between T cells, B cells and macrophages. Transplant Rev (1972) 2.44

Modulation of cytokine production by transforming growth factor-beta. J Immunol (1989) 2.42

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41

Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res (2000) 2.37

TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol (1992) 2.34

Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science (1985) 2.27

Role of C3 in in vitro lymphocyte cooperation. Nature (1974) 2.27

T-T interactions in the induction of suppressor and helper T cells: analysis of membrane phenotype of precursor and amplifier cells. J Exp Med (1977) 2.22

Measurement of DNA antibodies by double antibody precipitation. Ann Rheum Dis (1973) 2.21

Public health aspects of viral haemorrhagic fevers in Britain. R Soc Health J (1978) 2.18

Antibody-mediated suppression of the immune response in vitro. I. Evidence for a central effect. J Exp Med (1970) 2.17

Cell-mediated immune response in vitro. II. The role of thymus and thymus-derived lymphocytes. Cell Immunol (1972) 2.15

Spongiform encephalopathy of Rocky Mountain elk. J Wildl Dis (1982) 2.11

Tolerance of T-cell clones is associated with membrane antigen changes. Nature (1983) 2.10

The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis. Q J Med (1979) 2.07

Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol (1988) 2.06

Suppressor cell induction in vitro. II. Cellular requirements of suppressor cell induction. Eur J Immunol (1976) 2.05

Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol (1998) 2.03

The clinical significance of mediators of cellular immunity. Clin Allergy (1971) 2.03

Isolated microscopic haematuria in the genitourinary clinic: the value of renal biopsy. Int J STD AIDS (1997) 2.02

Relationship between antigen and antibody-induced suppression of immunity. Transplant Rev (1972) 2.02

Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis. Br Med J (1978) 2.01

Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol (1990) 2.01

Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A (1998) 2.01

A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum (1985) 1.99

Restrict genetic susceptibility tests. Nature (1998) 1.99

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96

Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol (1998) 1.96

Cell interactions in the immune response in vitro. 3. Specific collaboration across a cell impermeable membrane. J Exp Med (1972) 1.96

Tissue-specific expression of the alternative oxidase in soybean and siratro. Plant Physiol (1992) 1.94

Antibody-mediated suppression of the immune response in vitro. II. A new approach to the phenomenon of immunological tolerance. J Exp Med (1970) 1.93

Spongiform encephalopathies in Cervidae. Rev Sci Tech (1992) 1.92

Cell-mediated immune response in vitro. 3. The requirement for macrophages in cytotoxic reactions against cell-bound and subcellular alloantigens. J Exp Med (1972) 1.89

Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 1.87

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol (1991) 1.87

Selective regulation of cytokine induction by adenoviral gene transfer of IkappaBalpha into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-kappaB independent. J Immunol (1999) 1.86

A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85

Role of macrophages in in vitro induction of T-helper cells. Nature (1975) 1.84